Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,422 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,422 Papers indexed
1,440 Papers AI scored
39,422 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-10-18 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39422 results
B
Infectious Complications During Reinduction in Children with Relapsed Acute Lymphoblastic Leukemia: A Descriptive Analysis.
PMID 40884783 Published: 2025-08-30 Ingested: 2026-08-02 12:04 AM Pediatric hematology and oncology
AI -
Standard 75.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 80.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
PMID 39938007 Published: 2025-06-05 Ingested: 2026-08-02 12:04 AM Blood
AI -
Standard 75.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 75.1; sample size: 40.0; recency: 90.0; abstract quality: 85.0.

B
Impact of microwave ablation on survival rates and recurrence in hepatic malignant tumors.
PMID 39136926 Published: 2024-08-13 Ingested: 2026-08-02 12:01 AM Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AI -
Standard 75.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 30.1; sample size: 70.0; recency: 90.0; abstract quality: 85.0.

B
Five-year follow-up outcomes after phase 1 trial of mesenchymal stromal cells for periventricular hemorrhagic infarction in preterm infants.
PMID 42241571 Published: 2026-05-18 Ingested: 2026-08-02 12:06 AM Stem cells translational medicine
AI -
Standard 75.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 40.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 75.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 20.0; sample size: 80.0; recency: 100.0; abstract quality: 100.0.

B
Do thyroid nodules in the isthmus carry a higher risk of malignancy? A systematic review and meta-analysis.
PMID 42228113 Published: 2026-06-01 Ingested: 2026-08-02 12:07 AM European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
AI -
Standard 75.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 100.0; recency: 100.0; abstract quality: 85.0.

B
Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.
PMID 42167809 Published: 2026-05-21 Ingested: 2026-08-02 12:06 AM Journal for immunotherapy of cancer
AI -
Standard 75.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer.
PMID 42163826 Published: 2026-05-21 Ingested: 2026-08-02 12:06 AM Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
AI -
Standard 75.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 30.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
Capmatinib targeted therapy in MET-fusion driven radiation induced glioma.
PMID 42130628 Published: 2026-04-28 Ingested: 2026-08-02 12:06 AM Frontiers in oncology
AI -
Standard 75.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 365 of 3286
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic